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Abstract 
Molecular typing is increasingly essential to tuberculosis (TB) control programmes, providing 
public health practitioners with a tool to characterize transmission patterns, track the 
emergence and spread of strains of M. tuberculosis complex (MTC) in populations. While 
molecular typing is already used extensively as a tool for TB control in many developed 
settings across the globe, its use in resource-poor settings is still limited. Moreover, 
information on the role, contribution and burden of nontuberculous mycobacteria (NTM) and 
other pathogens in aetiology of TB-like syndromes is also lacking in such settings.  
The broad objective of this dissertation was to determine the genetic diversity of MTC and 
their drug resistance profiles as well as the prevalence of NTM and other potentially 
pathogenic bacteria among TB suspects in Northeastern, Tanzania in order to generate 
insights that may inform the design of a rational TB control programmes.  
A total of 18 distinct spoligotypes were identified in this study area, with CAS1-KILI and 
EAI8 being the most predominant families. Major lineages prediction by conformal Bayesian 
network (CBN) revealed that 70% of TB infections in this area is due to modern lineages, 
whereas 30% of TB infections is due to the ancestral lineages mainly of Indo-oceanic lineage. 
The study also revealed that the overall proportions of any drug resistance and MDR-TB were 
12.7% and 6.3% respectively. With the prevalence of any drug resistance and MDR-TB 
among new cases being 11.4% and 4.3% respectively, among previously, treated cases were 
22.2%. The prevalence of NTM was found to be 9.7 %, with HIV being a significant predictor 
of NTM detection (P < 0.001). Four out of 30 patients with NTM diagnosed by culture 
received 1st line anti-TB treatment suggesting that a proportion of patients diagnosed by smear 
microscopy (4/65, 6.2%) were mistreated as TB patients. Our findings further showed that 17 
(4.6%) out of 372 TB suspects were due to pulmonary nocardiosis. 
  
Overall this dissertation has revealed that TB is still a major problem in Tanga and is 
characterized by a diverse array of MTB strains. Additionally, modern MTB strains contribute 
significantly to TB infections in this area.  High proportions of anti-TB drug resistance among 
new treated cases observed suggest that more efforts need to be done to identify individual 
cases at facility level for improved TB control programmes. Inefficient screening of TB 
patients and a prevalent increase of NTM may contribute to both unrealistic and 
mismanagement of TB cases. A diverse array of pathogenic Nocardia species among TB 
suspects further indicates that they are likely cause of human disease in this population. 
Therefore, need to integrate NTM and pathogens causing TB-like syndromes in diagnosis and 
management of TB is urgent. Results of these investigations contribute to the understanding 
of the dynamics of TB transmission in resource poor settings of Tanzania and highlight key 
factors that should be considered in the development of rational approaches to design 
effective TB prevention and control programmes in the country. 
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Chapter One  Introduction  
1.1 A review of Mycobacterium tuberculosis Complex and Tuberculosis Disease 
1.1.1 M. tuberculosis overview 
M. tuberculosis is known to be the most prominent member of M. tuberculosis complex 
(MTC) causing TB in humans, with an estimated 9.4 million new cases and about 1.8 
million deaths worldwide each year [2]. 
M. tuberculosis is an aerobic, slow-growing, acid-fast, rod-shaped bacterium belonging to 
the genus Mycobacterium, order Actinomycetales that comprises a large number of well-
characterized species, several of which are associated with the human and animal disease. 
Other known human pathogens include Mycobacterium ulcerans, the causative agent of 
Buruli ulcer and Mycobacterium leprae, the cause of leprosy. Other classical species of 
the MTC other than M. tuberculosis, include Mycobacterium africanum (of various 
subtypes and variants), Mycobacterium microti (voles and other small rodents), and 
Mycobacterium bovis (along with the widely used vaccine strain M. bovis bacillus 
Calmette-Gue´rin [BCG]). 
 
Newly recognized additions to the MTC include Mycobacterium caprae (goats) and 
Mycobacterium pinnipedii (seals and sea lions) [3]. Though not currently an officially 
described organism, “Mycobacterium canettii” is also widely accepted as a member of 
the MTC [4]. Several studies have shown > 99% DNA homology among subspecies of 
the MTC [5]. However, they differ in their host range, epidemiology, clinical picture in 
human, as well as laboratory phenotype. 
 
Like other Mycobacterium spp, M. tuberculosis is cytochemically Gram-positive. A 
characteristic feature of these mycobacteria is their extremely resilient cell envelope that 
contains a rich variety of lipids such as mycolic acids, glycolipids, and polysaccharides. 
This unique cell wall is also responsible for the acid-fast staining property of 
mycobacteria. The cell wall lipids bind carbol fuchsin that resists decolorization by the 
acid-alcohol used in Ziehl-Neelsen (ZN) staining technique, hence bacilli that stain by 
this method are commonly referred to as acid-fast or ZN-positive [6].  
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1.1.2 Tuberculosis Disease  
Tuberculosis (TB) has afflicted humankind from the time immemorial. It is responsible 
for millions of death occurring each year worldwide. Evidence of spinal disease has been 
found in Egyptian mummies of several thousand years BC (Before Christ) and references 
to TB are found in ancient Babylonian and Chinese writings. With the help of molecular 
genetic studies M. tuberculosis, the most common cause of TB in humans worldwide is 
believed to have a progenitor dating back to about 3 million years old [7]. 
1.1.3 TB Transmission and Pathogenesis 
The advent of genomic revolution in the last decade has to a large extent enabled the 
application of a  variety of powerful tools, such as proteomics, large-scale 
transcriptomics, comparative genomics, and structural genomics studies in the field of TB  
research that have resulted in a great understanding of the biology  and pathogenesis of 
the tubercle bacilli. M. tuberculosis has a slow generation time of approximately 24 hours 
and takes three to four weeks to form colonies in vitro. 
TB is a communicable disease and patients with pulmonary TB are the most important 
source of infection. Infection occurs by inhalation of droplet nuclei, which are particles of 
about 1–5 μm in diameter encompassing M. tuberculosis, coughed up by patients with 
active pulmonary TB.  
The risk of infection (Figure 1) is a function of several factors such as the infectiousness 
of the source case, the proximity of contact, the infectious dosage inhaled, and the 
immune competence of the susceptible host [1,8–10]. The primary route of infection 
involves the lungs. Inhaled droplet nuclei evade the defences of the bronchi due to their 
small size and penetrate into the terminal alveoli where are engulfed by phagocytic 
immune cells (macrophages and dendritic cells). Studies also show that M. tuberculosis 
can infect non-phagocytic cells in the alveolar space like M cells, alveolar endothelial, 
and type 1 and type 2 epithelial cells (pneumocytes) [11–13]. 
During the early phase of infection M. tuberculosis  is internalized by phagocytic immune 
cells, multiplies intracellularly, and immune cells loaded with the bacteria may cross the 
alveolar barrier to cause systemic dissemination [1,12,14]. The intracellular replication 
and simultaneous dissemination of the pathogen to the pulmonary lymph nodes and to 
various other extrapulmonary sites occur prior to the development of the adaptive 
immune responses. This elucidates the exceptional competence of M. tuberculosis to 
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establish a protected niche where they can avert elimination by the immune system and 
persevere indefinitely [15,16]. 
An effective cell-mediated immune response may develop in the range of 2–8 weeks 
following infection that ceases further multiplication of the tubercle bacilli (Figure 1). 
Granulomas that hinders further replication and spread of the tubercle bacilli is finally 
formed from the activated T lymphocytes, macrophages, and other immune cells. M. 
tuberculosis evolves an effective strategy to evade the immune response leading to the 
survival and persistence of some bacilli in a non-replicating state within the host called 
latent TB infection (LTBI), which may take up to 3 years [9,16–18]. 
During this stage, more slowly developing extrapulmonary lesions, such as those in bones 
and joints, often characterized by chronic back pain, may occur in some individuals. This 
assumption is evidenced by the fact that, M. tuberculosis has been cultured and the 
presence of M. tuberculosis DNA has been verified from lung tissues of individuals who 
died from other diseases and who did not manifest with any pathological sign of TB 
disease [19,20]. When an ensuing defect in cell-mediated immunity occurs, it may elicit 
reactivation of inert bacilli resulting into an active disease many years after the infection 
(reactivation TB). 
 
In regards to the HIV/TB co-infection individuals, studies show that one-third of exposed 
HIV-negative individuals become infected, and 3 to 5% of them develop TB in the first 
year, an additional 3 to 5% of those infected develop TB later in life. It is speculated that 
most adult TB in non-HIV-infected patients is caused by reactivation of pre-existing 
infection [21]. HIV-positive persons infected with M. tuberculosis have a 50% chance of 
developing reactivation (post primary) TB at some time in their lives. Such individuals 
and those with immunosuppression can also be newly infected with M. tuberculosis and 
may show rapid progression to active disease [22]. 
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1. 2 Epidemiology and Burden of TB/HIV co-infection 
TB remains a major public health problem in many parts of the world regardless of the 
efforts to combat the disease. Africa alone carries a huge burden of TB estimated at 30% 
of the global cases in 2009, second after Asia (50%). Approximately 41% of the highest 
burdened countries (HBCs) with TB worldwide are in Africa [23] (Figure 2). TB burden 
in Africa is largely fuelled by human immune deficiency virus (HIV) epidemic. In 2009, 
the region accounted for about 11-13% of the TB deaths associated with HIV-positive 
[23] (Figure 3).  
Figure 1: Progression of natural cause of events and outcome in an immunocompetent individual 
following exposure to droplet nuclei containing M. tuberculosis expectorated by a source case of 
sputum smear-positive pulmonary (Open) TB [1]. 
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General weak health care systems, inadequate laboratory services, plus conditions 
promoting transmission of infection, and the emergence of multidrug- resistant (MDR-
TB) strains have compounded the problem [24–26]. Other compounding factors which 
have aggravated the increased TB trend in the region include poverty, malnutrition, poor 
living conditions resulting to overcrowding, inadequate access to free and affordable 
health care services and reliance on traditional healers [27]. 
 
Figure 2: Estimated TB incidence in 2010 [28] 
 
Figure 3: Estimated HIV prevalence in new cases of TB in 2010 [28]  
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1.2.1 World situation of MDR-TB 
Multidrug-resistant (MDR) -TB has emerged as a crucial threat to TB control. Drug 
resistant (DR) -TB is widespread and is found in all countries of the world [23]. MDR-
TB caused by tubercle bacilli resistant to at least one of the first-line anti-TB drugs, 
Rifampicin (RMP) and or Isoniazid (INH) was declared a global burden [29]. Both 
biological, as well as socioeconomic factors, have been responsible for the emergence of 
DR-TB, which is a purely manmade phenomenon; a result of sub-optimal chemotherapy 
[29,30]. 
Estimates of DR-TB incidence are difficult to obtain largely due to inadequate laboratory 
facilities for drug susceptibility testing (DST) in most resource-poor endemic countries 
[31]. For example, only 24,511 cases of the 250,000 expected MDR-TB cases were 
enrolled for the treatment in 2009 [32]. While the numbers of expected MDR-TB cases 
rose to 650,000 of which only 46,000 cases were enrolled for treatment in 2010 [28]. 
These trends indicate the need for continuous improvement in both diagnosis and 
management of DR-TB, especially in  resource-poor countries in order to reduce 
morbidity, mortality, economic loss, further spreading of infection and emergence of 
MDR strains [33]. Extensively drug-resistant-TB (XDR-TB) caused by bacterial strains 
resistant to the two first-line anti-TB (RMP and INH) and to second line drugs (injectable 
aminoglycosides and fluoroquinolones) is another serious threat to global health [23]. 
1.2.2 TB and MDR-TB situation in Tanzania 
Tanzania is among the 22 HBCs with respect to the number of incident TB cases [34]. 
Previous reports revealed that up to the mid-eighties, the annual number of cases 
identified and treated in the country was manageable. However, increased HIV epidemic 
has reversed the situation [35,36]. For instance, in just 5 years (1980-1985), the number 
of TB cases notified tripled from 5000 to 15,000. In 2006, over 62,000 TB cases (157 
cases per 100,000 population) were reported, while WHO estimated the incidence to be 
312 per 100,000 population [34,37]. Although the routine TB surveillance data in the 
country have been consistent over the years, there are still areas of uncertainty, which 
makes the routine data not easily translated into an approximation of TB incidence as an 
indicator for the burden of disease [38]. 
Information on anti-TB drug resistance levels is a vital management tool for evaluating 
the performance of National TB control programmes (NTPs) [39]. While resistance in 
previously treated patients is an essential indicator of current treatment practices in the 
                                                                                                                                       Introduction 
7 
 
community, drug resistance in previously untreated (new) patients mirror the 
transmission of disease with resistant strains, and indicates the complications that the 
NTPs will face during administering chemotherapy. 
Case detection rate of TB and prevalence of multidrug-resistant (MDR) TB in 
Tanzania remain low with about 1,300 MDR-TB cases reported in 2007 consequently 
to improved quality of services and evaluation. Data regarding anti-tuberculosis drug 
resistance is only available from a handful of selected settings and studies [40,41]. 
Treatment of MDR cases in Tanzania consists of a standardized MDR-TB regimen 
based only on drug susceptibility results for the first-line medications, isoniazid, 
rifampicin, streptomycin and ethambutol [42]. Based on this account, MDR-TB in 
Tanzania reflects a unique population with little to no exposure to second-line 
medications and with a relatively low background prevalence of drug resistance. 
1.3 Molecular mechanisms of drug resistance in M. tuberculosis 
Advances in molecular biology techniques as well as the existence of new information 
generated after deciphering the complete genome sequence of M. tuberculosis [43,44], 
have enabled understanding of the mechanisms of resistance to the principal anti-TB 
drugs. Specific gene mutations associated with drug resistance have been identified [45]. 
Drug resistance in M. tuberculosis arises from spontaneous chromosomal mutations at a 
low frequency through the subsequent acquisition of mutations at multiple loci [27]. To 
date, the most common mutations  associated with drug resistance are described and 
publically accessible on the DR-TB mutation database [46]. Molecular mechanisms of 
drug resistance have been elucidated for the major first- and second-line drugs [47,48] 
Table 1. 
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Table 1 Mechanisms of drug resistance in M. tuberculosis 
 
 
Drug (year of 
discovery) 
 
 
MIC 
µg/ml 
Genes 
involved 
in 
resistance 
 
 
 
Gene function 
 
 
 
Role 
 
 
 
Mechanism of action 
 
Mutation 
frequency 
% 
Isoniazid (1952) 0.02 – 
0.2 
katG 
 
 
inhA 
Catalase–peroxidase 
 
 
Enoyl acyl carrier protein (ACP) 
reductase 
Pro- drug 
conversion 
 
Drug target 
Inhibition of mycolic acid 
biosynthesis and other 
multiple effects 
50 – 95 
 
 
8 - 43 
Rifampicin (1966) 0.05 - 1 rpoB ß subunit of RNA polymerase Drug target Inhibition of RNA 
synthesis 
95 
Pyrazinamide (1952) 16 – 50 
pH 5.5 
pncA Nicotinamidase/pyrazinamide Prodrug 
conversion 
Depletion of membrane 
energy 
72 - 97 
Ethambutol (1961) 1 - 5 embB Arabinosyltransferase Drug target Inhibition of 
arabinogalactan synthesis 
47 - 65 
Streptomycin (1944) 2 - 8 rpsL 
 
rrs 
 
gidB 
S 12 ribosomal protein 
 
16S rRNA 
 
rRNA methyltransferase  
(G527 in 530 loop) 
Drug target 
 
Drug target 
 
Drug target 
Inhibition of protein 
synthesis 
52 – 59 
 
8 – 21 
 
? 
Amikacin/Kanamycin 
(1957) 
2 - 4 rrs 16S rRNA 
 
Drug target Inhibition of protein 
synthesis 
76 
Capreomycin (1960)  tlyA 2’-O-methyltransferase Drug target   
Quinolones (1963) 0.5 – 2.5 gyrA 
 
gyrB 
DNA gyrase subunit A 
 
DNA gyrase subunit B 
Drug target 
 
Drug target 
Inhibition of DNA gyrase 75 - 94 
Ethionamide (1956) 2.5 - 10 etaA/ethA 
 
inhA 
Flavin monooxygenase 
 
 
Prodrug 
conversion 
Drug target 
Inhibition of mycolic acid 
synthesis 
56 
PAS (1946) 1 - 8 thyA Thymidylate synthase Drug 
activation? 
Inhibition of folic acid 
and iron metabolism 
36 
MIC = Minimum inhibitory concentration; PAS = Para-amino salicylic acid; ? = Mutation frequency not determined.  Source:[48]
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1.4 Diagnosis of TB  
The diagnosis of active TB greatly depends on initial clinical suspicion and radiological 
examination, followed by subsequent laboratory confirmation using microbiological 
techniques primarily sputum smear microscopy. TB and MDR-TB are typically common 
in resource-limited settings, precise diagnosis, and relevant treatment is necessary to 
prevent the spread of DR-TB within communities. However, these tools do not allow for 
the prediction of drug resistance. 
1.4.1 Radiologic examination 
Chest X-ray is the primary radiologic evaluation of suspected or proven pulmonary TB. 
Radiological presentation of TB may be variable but in many cases is quite characteristic. 
Radiology also provides essential information for management and follow-up of these 
patients and is extremely valuable for monitoring complications. Chest X-ray is useful 
but is not specific for diagnosing pulmonary TB. Moreover, TB can present with 
symptoms and atypical radiologic findings that are indistinguishable from those of 
community-acquired pneumonia [49,50]. Therefore, an acid-fast bacilli (AFB) smear and 
bacteriological culture tests should be performed for patients with symptoms that are 
compatible with or suggestive of TB. 
1.4.2 AFB smear microscopy  
Direct sputum microscopy is the primary method for diagnosing pulmonary TB in many 
resource-poor settings. A major shortfall of conventional microscopy is its relatively low 
sensitivity compared with culture, especially in patients co-infected with HIV [51,52]. 
Moreover, smear microscopy may be costly and inconvenient for patients, who must 
make multiple visits to health facilities and submit multiple sputum specimens over 
several days. Conventional light microscopy of Ziehl-Neelsen (ZN)–stained smears 
prepared directly from sputum specimens is the most widely available test for diagnosing 
TB in resource-limited settings. ZN microscopy is highly specific, but its sensitivity is 
variable (20%–80%). Conventional fluorescence microscopy is more sensitive (10%) 
than the Ziehl-Neelsen and takes less time, but it is limited by the high cost of mercury 
vapor light sources, requires  dark room and regular maintenance [53]. Light-emitting 
diodes (LED) have been developed to offer fluorescence microscopy without the 
associated costs [54]. The WHO recommends that conventional fluorescence microscopy 
is replaced by LED microscopy and that LED microscopy be phased in as an alternative 
for conventional Ziehl-Neelsen light microscopy [54]. 
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1.4.3 Mycobacterial culture 
Acid-fast microscopy is easy and quick, but it does not confirm a diagnosis of TB 
because some acid-fast bacilli are not M. tuberculosis. Therefore, a culture is done on all 
initial samples to confirm the diagnosis. A positive culture for M. tuberculosis confirms 
the diagnosis of TB disease. In an ideal situation, it is recommended that culture 
examinations be completed on all specimens, regardless of AFB smear results. 
Mycobacterial culture is more sensitive, but the growth of TB bacilli on traditional solid 
medium requires 4–8 weeks, which delays appropriate treatment in the absence of a 
confirmed diagnosis. Culturing mycobacteria is mainly done on solid media, the 
Lowenstein-Jensen slope, or in broth media. These methods are slow, with cultures from 
microscopy-positive specimen ranging from 2–4 weeks and for a microscopy-negative 
specimen from 4–8 weeks. Liquid media is significantly faster (between 10 and 14 days) 
and is better for isolation, compared to solid media. For drug susceptibility testing (DST), 
the delay may be reduced to as little as 10 days compared to 4–6 weeks with conventional 
solid media. Liquid systems are more sensitive for detecting mycobacteria and may 
increase the case yield by 10% compared to solid media [55]. With increased sensitivity 
and reduced delays, liquid systems may contribute significantly to improved patient 
management. Liquid systems are, however, more prone to contamination by other 
microorganisms. In experienced laboratories, approximately 5% –10% of specimens fail 
to yield results because of contamination [56]. Procedures to prevent cross-contamination 
(due to carryover of bacilli from positive to negative specimens) should also be strictly 
followed, especially where increased numbers of positive specimens are processed in 
high-incidence countries [57,58]. Increased bacterial contamination and an increased 
frequency of nontuberculous mycobacterial (NTM) isolation need to be addressed. A 
rapid method to differentiate the M. tuberculosis complex from other mycobacterial 
species is essential. Several tools that can automatically detect M. tuberculosis growth in 
the laboratory, such as the Bactec “Mycobacterial Growth Indicator Tube 960” (MGIT 
960; Becton-Dickinson, Sparks, MD, USA) and the MB/BacTAlert® 3D (Biomérieux, 
Durham, NC, USA) have been developed. Unfortunately, these automatized incubators 
are expensive, and not readily available outside reference centres in resource-poor 
settings. 
1.4.4 Diagnosis of MDR-TB 
Early detection of drug resistance TB enables proper treatment that has a great impact in 
the better control of the disease. Detection of drug-resistant bacilli can be done by culture 
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based or genome-based techniques. Recent advances in molecular biology and a better 
understanding of the molecular mechanisms of drug resistance TB have provided new 
tools for its rapid diagnosis and for the rapid detection of drug resistance. Several new 
genotypic and phenotypic methods for rapid diagnosis and detection of drug resistance 
have been developed and tested in both M. tuberculosis strains and in clinical specimens. 
1.4.2.1 Phenotypic drug susceptibility testing 
Phenotypic DST or culture-based methods performed on either solid or liquid media as 
direct or indirect tests are precise and less expensive. However, their turn-around time is 
long owing to dependence on the growth of M. tuberculosis [59].  
Commercial automated liquid culture DST methods such as BacT/Alert®3D system 
(bioMerièux Inc, Durham, North Carolina, USA), Mycobacteria Growth Indicator Tube 
(MGIT) (Becton Dickinson, Sparks, MD), BACTEC MGIT960 system (Becton 
Dickinson, Sparks, MD) and Versa TREK system (Trek Diagnostic Systems, West Lake, 
Ohio, USA) have been developed. The methods have improved the turnaround time 
because of sensitive automation and the fact that M. tuberculosis grows relatively faster 
in liquid compared to solid media, however, they are expensive both in terms of 
equipment and expertise for most resource-poor-settings [60].  
Alternative ‘in-house’ methods for rapid DST of M. tuberculosis using solid culture 
media have been developed with the aim of shortening the turnaround time. Such 
methods include Mycobacteriophage-based methods like (Fast Plaque assay and 
Luciferase reporter phages), E-test, nitrate reductase assay, microcolony method and the 
tuberculosis colorimetric culture medium –TK® medium [60–62]. 
1.4.2 .2 Genotypic drug susceptibility testing 
Genotypic DST methods target well-characterised resistance-associated mutations to 
identify drug-resistant M. tuberculosis. RMP resistance is notably appropriate for 
genotypic DST since about 95% of mutations conferring resistance to RMP in RMP-
resistant clinical M. tuberculosis isolates occur mostly in the 81bp rifampicin resistance 
determining region (RRDR) of the rpoB gene [27,63–66]. 
Molecular methods, such as Xpert MTB/RIF assay (Cepheid; Sunnyvale, CA, USA), and 
the GenoType MTBDRplus assay in combination with GenoType MTBDRsl (Hain Life 
science, GmbH, Nehren, Germany), have shown excellent correlation with phenotypic 
                                                                                                                                            Introduction 
12 
 
DST results with specificities and sensitivities > 90% and have been endorsed by the 
WHO [34,67].  
Molecular detection of resistance to other anti-TB drugs, such as INH and ethambutol 
(EMB), is, however, more complex and requires detection of mutations in multiple genes 
for a good correlation with phenotypic results [65]. INH resistance-associated mutations 
have been found in the katG and inhA genes, however, approximately 15 to 25% of INH-
resistant isolates do not contain mutations in these regions, suggesting that other sites 
may also be involved in resistance [68]. 
Accurate genotypic DST for first and second-line anti-TB drugs is, still technically 
demanding. Understanding of the molecular mechanisms of anti-TB drug resistance and 
improved multiparametric detection technology will make genotypic DST a more 
powerful technique in future. 
1.5 Strain Identification for M. tuberculosis 
The distribution of TB in different geographic regions is characterized by the prevalence 
of different MTB strains with varied virulence and drug resistance. Environmental and 
host factors are believed to be responsible for the transmission and prevalence of different 
MTB strains [69]. One of the decisive measures of any TB control program is the 
capacity to determine where transmission occurs in order to prevent further spread of 
infection and prevent active disease by identifying newly infected individuals and 
providing them with timely preventive therapy. 
The advent of genetic fingerprinting of MTB has substantially improved the knowledge 
and ability to determine patterns of transmission in communities, as well as establishing 
transmission links between individuals [70]. Several molecular techniques have been 
used for studying the molecular epidemiology of TB. 
1.5.1 Genotyping of mycobacteria  
 Genotyping of isolates from patients is useful in various situations; like to confirm the 
occurrence of cross-contamination in the laboratory. Approximately 3% of patients from 
whom MTB is apparently isolated in clinical laboratories do not have TB; the positive 
cultures are due to cross-contamination [71]. If MTB is isolated from a specimen but the 
clinical findings do not suggest the presence of disease, genotyping of the isolate as well 
as other MTB strains handled concurrently in the laboratory can strongly imply the 
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occurrence of cross contamination and lead to the discontinuation of anti-TB medications 
[72]. 
There exist broad variability in the genotypes of MTB isolates from patients with 
epidemiologically unrelated TB, in which the genotypes of isolates from patients who 
were infected by a common source are identical [73]. Consequently, clustered cases of 
TB, defined as isolates with identical or closely related genotypes, are a result of recent 
transmission. On the contrary, cases in which the isolates have distinctive genotypes 
generally represent a reactivation of infection acquired in the distant past [74]. 
Epidemiological studies have exploited DNA polymorphism associated with insertion  
elements and other repetitive DNA elements to differentiate clinical MTB isolates, based 
on the assumption that strains with identical DNA fingerprints are epidemiologically 
related. Strains without identical DNA fingerprints can be classified into clades or 
genogroups when they partially share polymorphic sites, like IS6110 insertion sites and 
spacer sequences in the polymorphic direct repeat (DR) region of the MTB genome [75–
77]. 
1.5.2 Genotyping methods 
Several repeat sequences have been identified in the genome of the MTC like the 
transposable elements [75], trinucleotide repeats [78], variable number tandem repeats 
(VNTR), mycobacterial interspersed repetitive units (MIRU) [79], and the DR region 
[80]. DR region is one of the most extensively studied loci, it consists of direct repeat 
sequences (36bp) interspersed with unique spacer sequences (34 to 41bp), referred to as 
direct variable repeat (DVR) sequences. DR region has evolved through the deletion of 
DVR sequences by homologous recombination, single nucleotide mutations, and the 
integration of IS6110 elements [81]. Events believed to be unidirectional and appearing 
over time, making the DR region an enlightening locus for studying the evolution and 
epidemiology of the MTC  [82,83]. 
 
1.5.2.1 Restriction Fragment Length Polymorphism (RFLP) 
Restriction-fragment-length polymorphism (RFLP) analysis of the distribution of the 
insertion sequence IS6110 in different strains is the standard approach used in genotyping 
MTB isolates. The method is based on differences in the IS6110 copy numbers for each 
strain, varying from 0 to about 25, and variability in the chromosomal positions of these 
IS6110 insertion sequences [84]. Isolates from patients infected with epidemiologically 
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unrelated strains of TB are said to have different RFLP patterns, and patients with 
epidemiologically related strains generally have identical RFLP patterns [77].  
IS6110 as a probe has favourable discriminatory power and is often used as a method of 
choice to differentiate strains of MTB [77]. However, absence or low copy number of 
IS6110 element in a significant number of MTB strains limit its usefulness [85]. 
 
1.5.2.2 Spoligotyping 
The introduction of new PCR-based methods like spoligotyping, MIRU-VNTR and 
double-repetitive-element PCR (DRE-PCR) typing permit simultaneous detection and 
epidemiologic typing of MTB [86,87]. Spoligotyping was developed as a tool to provide 
information on the structure of the DR region in individual MTB strains and in different 
members of the MTC. Basically, Spoligotyping is a reverse hybridization technique based 
on polymorphism in the DR locus of the mycobacterial chromosome [86]. The DR locus 
in MTB consists of 10 to 50 copies of a 36-bp direct repeat, separated from each other by 
spacers that have different sequences [88]. However, the spacer sequences between any 
two specific direct repeats are conserved among strains. Considering that strains differ in 
the presence or absence of specific spacers, the pattern of spacers in a strain can be used 
for genotyping hence the term spoligotyping (i.e. spacer oligonucleotide typing). 
 
Spoligotyping has two advantages over IS6110. Firstly, a small amount of DNA is 
required, hence can be performed on clinical samples or on strains of MTB shortly after 
inoculation into the liquid culture. Secondly, results of spoligotyping can be expressed in 
a digital format. Furthermore, the method is simple and results can be obtained within a 
single working day. However, spoligotyping has less power to discriminate among MTB 
strains than the IS6110-based genotyping [72]. 
 
1.5.2.3 MIRU-VNTR 
IS6110 fingerprinting, the gold standard method for MTB genotyping is laborious and 
requires weeks of MTB culturing, hindering the prospective use of typing for more 
efficient TB control programmes. Moreover, comparison of the fingerprints from large 
data sets requires highly standardized experimental and computerized procedures [89]. 
These problems complicate the determination of clustering rates in population-based 
studies and the exchange of data. 
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A most promising PCR-based method based on PCR amplification of multiple loci 
containing MIRU-VNTR repeats offers a potential solution to these drawbacks. The 
method has proved to be highly reproducible yielding bearable results [77]. It is much 
faster than IS6110-RFLP typing since it can be directly employed on crude extracts from 
colonies or early MTB cultures. 
 
Different MIRU-VNTR typing sets have been used, standard MIRU-12 loci set with 
discriminatory power close to IS6110-RFLP was proposed for molecular epidemiological 
studies in TB [79,90]. The traditional MIRU-12 set was replaced by the standard MIRU-
15 set, which is recommended as the standard for the routine molecular epidemiology of 
TB, outbreak surveys as well as population-based transmission studies. Presently, 
standard MIRU- 24 loci set  has been proposed for optimal discrimination of closely 
associated strains and for high-resolution phylogenetic studies [91]. 
1.6 Nontuberculous mycobacteria  
Mycobacteria other than MTC referred to as nontuberculous mycobacteria (NTM), have 
been associated with human diseases for nearly 80 years [92]. NTM are environmental 
opportunistic pathogens of humans and animals found in a wide variety of habitats that 
are also occupied by humans; including drinking water distribution systems and 
household water [93]. Due to the presence of NTM in the environment, various human 
activities influence their ecology and consequently their epidemiology. 
Although regarded as less pathogenic to humans, NTM can cause a wide range of clinical 
diseases, including chronic, debilitating pulmonary disease among elderly people and 
immunocompromised individuals, lymphadenitis in children, skin disease, and other 
extrapulmonary or disseminated infections [94]. 
Pulmonary NTM disease has been considered in the context of TB for two major reasons. 
Firstly, lung disease associated with NTM is often characterized by a cough, sputum 
production, haemoptysis, wasting illness, cavities on lungs and acid-fast organisms on 
sputum smear microscopy; hence can be mistaken for TB. Secondly, NTM isolates are 
often resistant to first-line anti-TB drugs, it may result in classifying and treating 
individuals with these isolates as MDR-TB cases [32]. 
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1.6.1 Epidemiology of NTM 
Although the epidemiology of TB is well documented, the prevalence and epidemiology 
of NTM disease in most developing countries remain largely unknown. Due to their 
ubiquitous presence in the environment, exposure to NTM is likely extremely common 
[95]. NTM can colonize the respiratory tract without causing disease such that finding 
NTM in respiratory secretions does not necessarily have clinical ramifications in all 
patients. Likewise in many developing countries, NTM disease is not reportable to public 
health institutions; consequently, epidemiological and surveillance data are not readily 
available in such settings. 
1.6.2 NTM Pulmonary Disease in Immunocompromised Patients 
NTM have been implicated in a large and increasing number of infections in both 
immunocompetent and immunocompromised hosts, mostly HIV-infected patients 
throughout the world [95–98]. Mycobacterium kansasii (M. kansasii), Mycobacterium 
xenopi (M. xenopi), Mycobacterium fortuitum (M. fortuitum) and Mycobacterium 
scrofulaceum (M. scrofulaceum) are the common opportunistic mycobacteria associated 
with HIV infections [99]. 
Information regarding HIV and pulmonary NTM co-infection from TB-endemic 
countries heavily stricken by HIV/AIDS are still limited [97]. Reports from Zambia and 
Tanzania documented pulmonary MAC as well as rarely reported species of M. sherrisii 
and M. lentiflavum  in HIV-positive patients [100–103]. 
Findings from a cohort of 1,060 HIV-positive patients in Thailand and Vietnam in 
southeastern Asian where the liquid culture was used show that, NTM were more 
frequently isolated than MTB. On the contrary, the report showed that NTM was rare in 
Cambodia, where only solid media was used [94].  
NTM disease has also been reported in individuals with lung cancers, hematologic 
genitourinary malignancies, and old age [104]. NTM disease is reported to be more 
predominant among patients receiving anti-Tumour necrosis factor-α (TNF-α) especially 
in individuals > 50 years old [105]. 
1.6.3 Diagnosis of NTM  
Pulmonary infections due to NTM are diagnosed with increasing frequency, partly due to 
increased populations at-risk but also because of improved awareness and diagnostic 
facilities, especially in developed countries. The number of species known to cause NTM 
infections has increased due to the sprawling use of molecular techniques. However, 
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diagnosis of NTM in TB/AIDS co-infection is greatly limited by HIV status of a patient. 
Since disseminated NTM infection is typically detected when the CD4+ T-Lymphocytes 
declines below 50µl in the majority of cases, the diagnosis of NTM is missed out [97]. 
 
According to the American Thoracic Society (ATS) and Infectious Diseases Society of 
America (IDSA) guidelines, diagnosis of NTM pulmonary disease should be based on a 
combination of clinical, radiological, histological and bacteriological criteria [106]. 
Due to the overlapping clinical manifestations of the diseases caused by M. tuberculosis 
and NTM, the specific diagnosis of NTM is complicated.  
Chances that NTM species are missed during diagnosis is largely attributed to: 
(i) poor diagnostic capabilities for culture and identification of NTM 
(ii) overburden by other diseases like Malaria, TB and HIV such that more focus 
from the health sector system and governments are paid to such other diseases 
(iii) lack of awareness among the public health personnel’s, and  
(iv) lack of standardized or accepted criteria to properly define and report NTM 
diseases. 
Conventional identification of mycobacteria is achieved by standard culture and 
biochemical methods, which is time-consuming. Increased NTM prevalence demands 
faster methods for identification and selection of appropriate therapy [107]. 
Molecular techniques complement conventional methods for appropriate species 
identification and may be considered as a new gold standard for NTM diagnosis. Several 
gene targets are known to be suitable for species differentiation. Partial genes sequencing 
for 65 kDa heat shock protein (hsp65), RNA polymerase beta-subunit (rpoß), essential 
protein secA1, superoxide dismutase (sodA), 16S rRNA and the 16S–23S ribosomal 
RNA internal transcribed spacer (ITS) have been evaluated for different NTM species 
[108–112].  
 
1.6.4 Management of NTM disease 
Despite the availability of advanced diagnostic tools and revised diagnostic criteria for 
NTM lung infection, the decision whether to treat a patient remains a subject of careful 
individual assessment taking into account the NTM species, the severity of disease, 
general condition, and underlying disorders. 
Clinical management approaches of patients diagnosed with MTC or NTM infections are 
different. Therefore, proper and timely identification of mycobacterial species causing 
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infections is a key to appropriate antimicrobial therapy [113]. As the understanding of the 
transmission of NTM between patients and their environment increases, the need for 
interventional trials designed to interrupt transmission in those susceptible to disease is 
increasingly evident. 
Since NTM are ubiquitous in nature and many questions pertaining NTM acquisition and 
pathophysiology remain unravelled, it has been difficult to devise practical and effective 
control strategies for diseases due to NTM. Increasing understanding of different NTM 
diseases has, however, given room for realistic discussion of NTM diseases prevention. 
Better understanding and correct identification of the reservoir(s) responsible for causing 
most NTM diseases (especially lung disease), factors associated with the disease 
transmission, and host susceptibility risks demand further research. 
1.7 Pulmonary Nocardiosis 
Nocardia species are increasingly isolated as infectious agents in immunocompromised 
patients, and at times, even among healthy individuals [114], causing infections ranging 
from pulmonary, cutaneous and subcutaneous human diseases [115]. Members of genus 
Nocardia are characteristically gram-positive, weakly acid-fast, strictly aerobic, 
filamentous branching bacilli that fragment into rod or coccoid shaped forms. Nocardia 
species are ubiquitous environmental bacteria capable of causing opportunistic infections 
in both human and animals [116,117] 
The most commonly isolated species in human include N. asteroids, N. farcinica, N. 
cyiriacigeorgica, N.nova, N. brasiliensis [118–120] and N. ignorata [121]. Pulmonary 
nocardiosis has been reported in patients with debilitating conditions, such as those with 
organ transplants, diabetes mellitus, leukaemia, and other malignancies [122]. 
The incidence of nocardiosis varies geographically according to a number of factors, like 
the prevalence of HIV infections, transplants, cancer, climate as well as socio-economic 
status, and laboratory capacity for Nocardia species detection and identification. 
Increased incidence of human nocardiosis may be attributed to the wide use of 
immunosuppressive drugs, improved diagnostic tests, and increased awareness among 
microbiologists and health professionals. Nonetheless, in many developing countries 
where other chronic lung diseases, particularly TB, are prevalent, Nocardia species are 
either missed or misidentified during diagnosis [123,124].  
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1.8  Problem Statement and Justification 
1.8.1 TB situation in Tanzania 
The last two decades in Tanzania like in other developing countries are marked by huge 
socioeconomic differences. These differences are reflected in the increased gap between 
the poor and the rich, lack of access to primary health care services, rapid population 
growth, as well as rural-urban migration. Consequently, this has negatively impacted the 
endemic diseases status like TB and HIV/AIDS pandemic. 
Early detection of TB has great potential to improve individual outcomes and reduce 
transmission within communities. Although improved diagnostics has potential to 
increase TB detection in patients with symptoms and signs of active TB, many patients, 
however, have few symptoms that fulﬁl deﬁnitions of suspected TB, or cannot reach the 
relevant health services because of barriers to access. 
Prevalence surveys of areas endemic for TB show that 50–60% of people with culture-
conﬁrmed TB do not report a chronic cough, and 15–25% report no symptoms [125]. 
Characteristic TB symptoms are less frequently observed in people with HIV [126], 
paediatric cases, and  may be concealed during pregnancy. This implies that if only 
passive case finding is used to identify new TB cases, then a large proportion of patients 
with active TB will continue to be undiagnosed. Tanzania continues to rely on passive 
case finding using clinical and radiological (where available) algorithm with the 
assistance of less sensitive smear microscopy for detection and identification of TB 
patients. In most cases, this has provided the unrealistic status of the actual prevalence of 
MTB among TB suspects [38]. Moreover, information on the different spoligotype 
families of MTC in Tanzania is limited, where available is restricted to small 
geographical settings. The absence of current data on the genetic structure of MTC limits 
identification of genotypes as well as understanding the transmission dynamics among 
patients who remain undetected by conventional methods. 
1.8.2 NTM situation in Tanzania 
Although notification of NTM disease is not required in many resource-poor countries, 
reports indicate that the prevalence of NTM diseases is increasing [127–129]. Since the 
habitats occupied by NTM (e.g. drinking water) are also shared by humans. Furthermore, 
the number of individuals with aggravated susceptibility to mycobacterial disease is also 
increasing (e.g. through immunosuppression) especially where the prevalence of HIV 
infection is high [93,130]. NTMs play a great role in TB-like disease than was previously 
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thought [131].  Despite evidence of isolation of NTM especially among HIV-infected 
individuals in Tanzania, no efforts have been made to establish the actual prevalence and 
clinical significance of NTM infections in the country [102,132]. Data on clinical 
infections due to NTM in Tanzania and in sub-Saharan Africa, in general, is still limited. 
NTM infections can confuse the diagnosis of TB as the tools for culture and identification 
of mycobacteria are often not available in these settings. Incomplete identification of 
mycobacterial species causing infections may have serious consequences, such as longer 
hospitalization time, the risk of co-infections as well as a selection of MDR strains. 
Clinical management approaches of patients diagnosed with MTC or NTM infections are 
different, therefore, proper and timely identification of mycobacterial species causing 
infections is likely to impact antimicrobial therapy [113]. The prevalence of diseases 
caused by NTM in the country will continue to increase as long as there is no guidelines, 
which are set in place to diagnose report and manage NTM infections. This trend, 
combined with antibiotic resistance, will continue to create havoc and difficulties in the 
management of mycobacterial infections. 
1.8.3 Pulmonary nocardiosis in Tanzania 
Pulmonary nocardiosis mimic pulmonary tuberculosis in most clinical and radiological 
manifestations. In Tanzania, where tuberculosis is one of the major public health threat 
clinical impact of nocardiosis as the cause of the human disease remains unknown, 
suggesting that infections due to this genus may be underdiagnosed and /or neglected as a 
cause of human diseases. 
1.8.4 Justification 
It is, therefore, apparent that correct and rapid identification of MTB, NTM and other 
bacterial pathogens causing TB-like syndromes such as Nocardia species is urgent, as 
they all constitute a clinical emergency that cannot be underrated. Need to carry out 
continuous surveys to provide correct information on the current genetic diversity of 
MTC, anti-TB drug resistance and the prevalence of NTM and other bacterial pathogens 
causing TB-like syndromes among TB suspects in Tanzania is particularly urgent in 
strengthening the fight against mycobacterial diseases and MDR-TB. 
 
                                                                                                                                             Objectives 
21 
 
Chapter Two  Objective of the Study 
This chapter describes the main objective and the specific objectives of this study. 
2.1 Main Objective 
The main objective of this study was to determine the current genetic biodiversity of M. 
tuberculosis complex and their drug resistance profiles as well as the prevalence of 
Nontuberculous Mycobacteria (NTM) and other potentially pathogenic bacteria among 
TB suspects in Northeastern, Tanzania. 
 
2.1.1 Specific Objectives 
i. To determine the genetic diversity of the M. tuberculosis complex strains in 
Tanzania using microarray-based spoligotyping and the mycobacterial 
interspersed repetitive units-variable number of tandem repeats (MIRU-VNTR). 
ii. To assess the magnitude of anti-TB drug resistance and associated risks among 
newly, and previously treated pulmonary TB patients at a facility-base level in 
Northeastern, Tanzania.  
iii. To determine the frequency and diversity of nontuberculous mycobacterial 
species among TB suspects in Northeastern, Tanzania. 
iv. To determining the role of nontuberculous mycobacteria in diagnosis, 
management and quantifying risks for TB transmission in Tanga, Tanzania. 
v. To determine the frequency of other potentially pathogenic bacteria among smear 
negative TB suspects in Northeastern, Tanzania. 
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Chapter Three  Materials and Methods 
This chapter describes the summary of the general methods used in the study. 
3.1 Study area and Patients 
3.1.1 Tanga city and Muheza District  
Tanga Region is located on the northeastern side of Tanzania mainland. The region lies 
between Latitudes 4o and 6o south of the Equator, and between longitudes 37o and 39o 
east of Greenwich. The Region is bordered by the Republic of Kenya in the north, 
Kilimanjaro Region in the northwest, Manyara Region in the west, Morogoro, and Coast 
Regions in the south and the Indian Ocean in the east (Figure 4). Muheza District and 
Tanga city have respectively a residential catchment population of 204,461 people with 
the average household size of 4.3 persons per household and 273,332 people with the 
average household size of 4.4 persons per household [133]. 
 
Figure 4. Map of Tanga indicating the study sites, the two hospitals, and two health centres are 
shown by octagon shapes and marked by letters A: Muheza Designated District Hospital 
(MDDH); B: Bombo Referral Hospital; C: Makorora Health Centre and D: Ngamiani Health 
Centre.  
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3.2 Inclusion and exclusion criteria 
All suspects aged 7 years and above, residing in Tanga city and Muheza District during 
the study period and informed consent from the patients were the inclusion criteria into 
the study; whereas temporary residents like visitors, unwillingness to consent and patients 
who had been on TB treatment for more than one week were excluded from the study. 
3.3 Study design 
A cross-sectional study was carried out between November 2012 and January 2013; 
suspects presenting with any of the following symptoms were recruited: the presence of 
symptoms suggestive of TB like a chronic cough for a period of ≥ 2 weeks, night sweats, 
fatigue, unexpected loss of weight, and fever. 
3.4 Sample collection 
Two sputum samples were collected from the consenting patients at the respective clinics, 
one spot sputum during the first visit and patients were provided with another sterile 
container to collect an early morning specimen. Direct smear microscopy using Ziehl 
Nelsen (ZN) - stain (Ngamiani and Makorora health centres) and fluorescence stain 
(Muheza Designated District hospital and Bombo referral hospital) were performed. 
Smear results were recorded in accordance with the WHO/IUTLD and National 
Tuberculosis and Leprosy Programme (NTLP) guidelines [134]. All early morning 
sputum samples were stored at -20oC and later transported to the mycobacteriology 
laboratory, University hospital Leipzig, Germany for culture and molecular analyses. 
Seven hundred and forty-four sputum specimens were collected from 372 TB suspects. 
Patients were also requested for HIV testing after pre-test counselling, with only 159 
patients consented for HIV testing. 
3.5 Sputum culture and identification of mycobacterial isolates 
Sputum specimens were decontaminated using N-acetyl-l-cysteine-sodium hydroxide 
method [135] and concentrated by centrifugation. All specimens were re-examined for 
the presence of acid-fast bacilli by fluorescence stain in Leipzig. Subsequently, all 
isolates were cultured in BacT/Alert 3D liquid culture system (BioMe´rieux, 
Marcy-l’Etoile, France) and on Löwenstein- Jensen and Gottsacker slants (Artelt-
ENCLIT GmbH, Wyhra, Germany). Gottsacker slopes contain sodium pyruvate for 
isolation of M. bovis. Cultures were incubated at 37°C for up to 8 weeks. 
GenoType®MTC (Hain Lifescience, Nehren, Germany) was used for confirmation of M. 
tuberculosis complex, whereas GenoType®CM/AS (Hain Lifescience, Nehren, Germany) 
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for confirmation of either common or accessory NTM. Additionally, NTM isolates not 
detected to the species level by Hain kits were subjected to the 16S rRNA and hsp65 gene 
sequencing.  
3.6 Drug susceptibility testing of M. tuberculosis complex isolates 
3.6.1 Phenotypic drug susceptibility testing 
Isolates were tested for resistance to rifampicin (RMP), isoniazid (INH), streptomycin 
(SM), ethambutol (EMB) and pyrazinamide (PZA) using BacT/ ALERT 3D system 
[136,137] in concentrations of 1 μg/ml for RMP, INH, and SM; 2 μg/ml for EMB and 
200 μg/ml for PZA. Bottles were incubated at 37°C and growth were monitored daily. An 
isolate was considered resistant to a drug under test when drug-containing bottle had a 
time to detection (TTD) that was less or equal to the TTD of 1% control bottle. 
 
3.6.2 Genotypic drug susceptibility testing  
Genotypic DST for RMP and INH was performed by using Genotype® MTBDRplus 
assay (Hain Life Science GmbH, Nehren, Germany). The assay uses a set of probes to 
affirm the test procedures (amplification and hybridization), a probe to identify MTC, 
eight rpoB wild-type (WT) probes encompassing the RRDR with no mutations, and four 
mutant probes expressly targeting the most common mutations conferring RMP 
resistance (D516V, H526Y, H526D, S531L). Additionally, it includes one WT and two 
mutant probes (S315T1 and S315T2) for the 315 region of the katG gene conferring high 
INH resistance, plus two other WT probes and four mutant probes (C15T, A16G, T8C 
and T8A) for the promoter region of the inhA gene, conferring low INH resistance. 
Genotypic detection of resistance to ethambutol (EMB) was done by using 
GenotypeMTBDRsl assay (Hain Life Science GmbH, Nehren, Germany). 
 
3.7 Genetic Analyses  
Eighty MTB isolates were eligible for molecular typing by using microarray-based 
spoligotyping and the conventional MIRU-VNTR typing. 
3.7.1 Microarray-based spoligotyping 
Spoligotyping of the MTB isolates was performed by using microarray-based 
spoligotyping format of the Array Strip platform (Alere Technologies GmbH, Jena, 
Germany) [138].  Briefly, genomic DNA of MTB isolates were amplified using 
polymerase chain reaction (PCR) with the primers DRa (5'-biotin labelled) and DRb. The 
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PCR products were hybridized on Array Strips using hybridization kit (Alere) at 60oC for 
1 hr and wash steps at 55oC, otherwise following manufacturer’s instructions. Recording 
of stained microarrays was done by using an Array Mate transmission reader (Alere). The 
binary code data were automatically compared with SpolDB4.0 and MIRU-VNTRplus 
(http://www.miru vntrplus.org/MIRU/index.faces) database to identify concordant 
species and lineages. 
 
3.7.2 MIRU-VNTR typing 
MIRU-VNTR typing was performed by PCR amplification of a panel of 21 MTB 
MIRU-VNTR loci using primers as described in the MIRU-VNTR standard protocol 
[91,139,140]. PCR mixture was prepared using the HotStar Taq DNA polymerase kit 
(Qiagen, Hilden, Germany). PCR products were analysed on 1.5% agarose gel against 
100bp DNA ladder (PEQ lab Biotechnologie GmbH, Erlangen, Germany) in TAE buffer 
electrophoresis for two hours at 100 constant voltage. The allele calling table provided in 
the MIRU-VNTR standard protocol [91] was used to assign the number of  alleles that 
correspond to the amplicon’s size. Results were entered into Ms. Excel sheet in a digital 
format. MIRU-VNTRplus database (http://www.miru-vntrplus.org/) was used to identify 
the MTB strains by similarity search and by a phylogenetic tree, using a categorical 
coefficient of one and a distance cut-off of zero. The UPGMA dendrogram was 
constructed from the strains genotypes using the online MIRU-VNTRplus database [141]. 
3.8 Norcadia isolates identification 
Nocardia isolates were presumptively identified based on their cultural and microscopic 
characteristics on Löwestein-Jensen media, blood agar and chocolate agar plates. 
Definitive identification was performed using biomèrieux ID 32C yeast identification 
system (Biomèrieux, Marcy-l’Etoile, France) following manufactures instructions and 
confirmed by 16S rRNA gene sequencing.  
 
3.9 Ethical considerations 
The protocol for this study was reviewed and approved by National Institute for Medical 
Research (NIMR), Tanzania (Reference number NIMR/HQ/R.8a/Vol.IX/1401). Informed 
consent was obtained from all participants of this study, the consent allowed for use of 
the collected sputum samples for the performance of other unspecified, TB, NTM and 
other bacterial pathogens diagnostic tests for research purposes. This consent was 
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obtained as written consent or, for illiterate participants, witnessed verbal consent. For 
illiterate participants, there was an independent witness present during the consenting 
process, who then signed the relevant witness section of the consent form. Ethical 
approval was obtained for the secondary use of the study data from the same ethical 
committee, which approved the consent form, including the section on the use of 
witnessed verbal consent for illiterate participants. 
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Figure 5. A flow chart summarizing Approach of the study 
Key: PDC= Periphery diagnostic centre; DST= drug susceptibility testing; MTBC = Mycobacterium tuberculosis complex; CM/AS = common or accessory 
nontuberculous mycobacteria; MIRU-VNTR = mycobacterial interspersed repetitive units-variable number of tandem repeats
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Summary  
Tanzania is one of the countries with the highest burden of tuberculosis (TB) in sub-
Saharan Africa, ranked 14th among the 22 high-burden countries. The last two decades in 
developing countries like Tanzania are marked by enormous socio-economic differences. 
These differences are reflected in the increased gap between the poor and the rich, lack of 
access to primary health care services, rapid population growth, as well as rural-urban 
migration. Consequently, this has negatively influenced the endemic diseases like TB and 
HIV/AIDS pandemic.  
Early detection of TB has great potential to improve individual outcomes and reduce 
transmission within communities. Although improved diagnostics has potential to 
increase TB detection in patients with symptoms and signs of active TB, many patients, 
however, have few symptoms that fulﬁl deﬁnitions of suspected TB, or cannot reach the 
relevant health services because of barriers to access. Passive case finding is the mainstay 
of case finding in most developing countries. This relies largely on sputum examination 
by smear microscopy, with culture only performed at reference centres for patients failing 
therapy of anti-TB drugs. Tanzania continues to rely on passive case finding using 
clinical and radiological (where available) algorithm with the assistance of less sensitive 
smear microscopy for detection and identification of TB patients. In most cases, this has 
provided the unrealistic status of the actual prevalence of MTB among suspected TB 
patients. 
Moreover, different species, strain families, and lineages of MTC are known to have 
differences in virulence, clinical presentation as well as transmission potential. However, 
information on the different spoligotype families of MTC in Tanzania is limited, where 
available is restricted to small geographical settings. The absence of current data on the 
genetic structure of MTC limits identification of genotypes as well as understanding the 
transmission dynamics among patients who remain undetected by conventional methods. 
Although notification of NTM disease is not required in many resource-poor countries, 
reports indicate that the prevalence of NTM diseases is increasing. NTMs play a great 
role in TB-like disease than was previously thought since the habitats occupied by NTM 
(e.g. drinking water) are also shared by humans. Furthermore, the number of individuals 
with aggravated susceptibility to mycobacterial disease is also increasing (e.g. through 
immunosuppression) especially where the prevalence of HIV infection is high.  Despite 
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evidence of isolation of NTM especially among HIV-infected individuals in Tanzania, 
efforts have not been made to establish the actual prevalence and clinical significance of 
NTM infections. Data on clinical infections due to NTM in Tanzania is limited.   
NTM infections can confuse the diagnosis of TB, as the tools for culture and 
identification of mycobacteria are often not available in these settings. Incomplete 
identification of mycobacterial species causing infections may have serious 
consequences, such as longer hospitalization time, the risk of co-infections as well as a 
selection of MDR strains. Clinical management approaches of patients diagnosed with 
MTC or NTM infections are different, therefore, proper and timely identification of 
mycobacterial species causing infections is likely to affect antimicrobial therapy. This 
trend, combined with antibiotic resistance will continue to create havoc and difficulties in 
the management of mycobacterial infections. The prevalence of diseases caused by NTM 
will continue to increase in many resource-poor settings like Tanzania unless guidelines 
are set in place to diagnose, report and manage NTM infections.  
The contribution of other potential pathogens known to cause TB-like symptoms such as 
pulmonary nocardiosis in many resource-poor settings like Tanzania remains unknown, 
largely due to insufficient diagnostic capabilities and overburdened with other diseases 
like malaria, TB, and HIV such that more focus from the health sector system, 
governments are paid to such other diseases. Several studies have shown that pulmonary 
nocardiosis which mimics pulmonary TB to be a common cause of human diseases in 
both developed and developing settings. Increased incidence of human nocardiosis may 
be attributed to the wide use of immunosuppressive drugs, improved diagnostic tests, and 
increased awareness among microbiologists and health professionals. Nonetheless, in 
many developing countries where other chronic lung diseases, particularly TB, are 
prevalent, Nocardia species are either missed or misidentified during diagnosis 
Need for correct and rapid identification of MTB, anti-TB drug resistance and the 
prevalence of NTM and other pathogens causing TB-like symptoms among TB patients 
in Tanzania is urgent, as they, all constitute a clinical emergency. 
Therefore, this research was conducted to bridge the information gaps urgently required 
in designing effective prevention and control strategies against tuberculosis and NTMs 
among TB suspects in Tanzania. Furthermore, it demonstrates the need to investigate the 
involvement of other potentially pathogenic bacteria characterized by TB-like symptoms 
that are seldom diagnosed in health facilities and hospitals. 
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Publication I: Molecular typing of Mycobacterium tuberculosis (MTB) has greatly 
enhanced the understanding of the population structure of MTB isolates and 
epidemiology of tuberculosis (TB). To characterize prevalent genotypes of MTB, 
microarrays-based spoligotyping and mycobacterial interspersed repetitive unit-variable 
number of tandem repeats (MIRU-VNTR) were applied on 80 isolates collected from 
primary health care facilities in Tanga, Northeastern Tanzania.  A total of 18 distinct 
spoligotypes were identified. The lineages by order of their predominance were EAI and 
CAS families (26.25%, 21 isolates each), LAM family and T superfamily (10%, 8 
isolates each), MANU family (3.75%, 3 isolates), Beijing family (2.5%, 2 isolates) and S 
family (1.25%, 1 isolate). Overall, sixteen (20%) strains could not be allocated to any 
lineage according to the SITVIT_WEB database. Results of major lineages prediction by 
CBN method suggest that 70% of TB infections in Tanga are due to the modern lineages, 
whereas 30% of TB infections is due to the ancestral lineages mainly of Indo-oceanic 
lineage. This suggests that modern MTB strains contribute significantly to TB infections 
in Tanga. The allelic diversity (h) for specific MIRU-VNTR loci showed a considerable 
variation ranging from 0.826 of VNTR locus 3192 to 0.141 of VNTR locus 2059. The 
allelic diversity for 11 loci (VNTR 3192, 2996, 2165, 960, 4052, 424, 4156, 2531, 1644, 
802 and 3690) exceeded 0.6, indicating highly discriminatory power. Seven loci (VNTR 
2163b, 2401, 1955, 577, 4348, 2687 and 580) showed moderate discrimination (0.3 ≤ h ≥ 
0.6), and three loci (VNTR3007, 154 and 2059) were less polymorphic. Findings of this 
study suggest that the TB cases in Tanga might be caused by a diverse array of MTB 
strain families that may be indicative of a cosmopolitan population with frequent 
migration and travel. Microarray-based spoligotyping and MIRU-VNTR could be reliable 
tools in detecting different MTB genotypes in high burden settings.  
 
Publication II: To determine the prevalence and risk factors associated with drug 
resistance tuberculosis (TB) at a facility-base level in Tanga, Tanzania. A total of 79 
Mycobacterium tuberculosis (MTB) isolates collected from among 372 (312 new and 60 
previously treated) TB suspects self-referred at four TB clinics during a cross-sectional 
study conducted from November 2012 to January 2013 were included. Drug 
susceptibility testing of the isolates to first-line anti-TB drugs was performed using 
BacT/Alert 3D system. Data on the patient's characteristics were obtained from a 
structured questionnaire administered to the patients who gave informed verbal consent. 
Unadjusted bivariate logistic regression analysis was performed to assess the risk factors 
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for drug resistant-TB. The significance level was determined at P < 0.05. The overall 
proportions of any drug resistance and MDR-TB were 12.7% and 6.3% respectively. The 
prevalence of any drug resistance and MDR-TB among new cases were 11.4% and 4.3% 
respectively, whereas among previously treated cases were 22.2% respectively. 
Previously treated patients were more likely to develop anti-TB drug resistance. There 
was no association between anti-TB drug resistances (including MDRTB) with the risk 
factors analysed. High proportions of anti-TB drug resistance among new and previously 
treated cases observed in this study suggest that additional efforts still need to be done in 
identifying individual cases at a facility-base level for improved TB control programmes 
and drug resistance survey should continuously be monitored in the country. 
 
Publication III: To determine the frequency and diversity of nontuberculous 
mycobacteria (NTM) among TB suspects in Northeastern, Tanzania. A cross-sectional 
study was conducted from November 2012 through January 2013. Seven hundred and 
forty-four sputum samples collected from 372 TB suspects were included in the study. 
Detection of NTM was done by using phenotypic, and Geno-Type® Mycobacterium 
CM/AS kits, additionally 16S rRNA and hsp65 gene sequencing was performed for 
isolates not identified by Hain kits. A binary regression model was used to analyse the 
predictors of NTM detection. The prevalence of NTM was 9.7 % of the mycobacterial 
isolates. Out of 36 patients with confirmed NTM infection, 12 were HIV infected with 
HIV being a significant predictor of NTM detection (P < 0.001). Co-infection with 
Mycobacterium tuberculosis (M. tb) was found in five patients. Twenty-eight NTM 
isolates were identified using Geno-Type® Mycobacterium CM/AS and eight isolates 
could not be identified. Identified species included M. gordonae and M. interjectum 6 
(16.7 %), M. intracelullare 4 (11.1 %), M. avium spp. and M. fortuitum 2 (5.5 %), M. 
kansasii, M. lentiflavum, M. simiae, M. celatum, M. marinum 1 (2.8 %) each. Of isolates 
not identified to subspecies level, we identified M. kumamotonense (2), M. 
intracellulare/kansasii, M. intermedium/triplex, M. acapulcensis/flavescens, M. 
stomatepiae, M. colombiense and M. terrae complex (1) each using 16S rRNA 
sequencing. Additionally, hsp65 gene sequencing identified M. kumamotonense, M. 
scrofulaceum/M. avium, M. avium, M. flavescens/novocastrense, M. 
kumamotonense/hiberniae, M. lentiflavum, M. colombiense/M. avium and M. 
kumamotonense/terrae/hiberniae (1) each. Results of the 16S rRNA and hsp65 gene 
sequencing were concordant in three and discordant in five isolates not identified by 
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GenoType® Mycobacterium CM/AS. NTM infections may play a vital role in causing 
lung disease and impact management of TB in endemic settings. GenoType® 
Mycobacterium CM/AS represents a useful tool to identify clinical NTM infections. 
However, 16S rRNA gene sequencing should be thought for confirmatory diagnosis of 
the clinical isolates. Due to the complexity and inconsistency of NTM identification, we 
recommend a diagnosis of NTM infections be centralized by strengthening and setting up 
quality national and regional infrastructure. 
 
Publication V: To understanding the role of NTM in diagnosis and management of TB 
in resource-poor settings a cross-sectional study was conducted at four peripheral 
diagnostic centres in Tanga, Tanzania. Two sputa (spot and one early morning) samples 
were collected for standard direct smear microscopy from 372 TB suspects. The culture 
was performed using BacT/Alert 3D system, Löwenstein-Jensen, and Gottsacker slopes. 
Identification of M. tuberculosis and NTM was done by using GenoType®MTBC and 
GenoType®CM/AS respectively. Eighty-one of the 372 (21.8%) patients were diagnosed 
as having Mycobacterium tuberculosis by the isolation of the organism from cultures of 
sputum. Further analysis of culture showed that 30/372 (8.1%) were NTM with 7/372 
(1.9%) cases of NTM classified as PTB patients. ZN stain had a sensitivity of 68.8% and 
produced 10 false negative results. On the other hand, Fluorescence stain had a sensitivity 
of 85.7% and gave seven false negative samples when compared with culture results. 
Weight loss (p = 0.0001), fatigue (p = 0.003), fever (p = 0.038) and night sweats (p = 
0.004), young population at the age of 18-40 years (p = 0.0352), males (p = 0.0025) were 
important risk factors for TB. Four out of 30 NTM diagnosed by culture received 1st line 
anti-TB treatment suggesting that a good proportion of patients (4/65, 6.2%) were 
mistreated as TB patients in Tanga. Inefficient screening of TB patients in resource-poor 
settings and a prevalent increase of NTM may contribute unrealistic TB cases. Need to 
integrate NTM diagnosis in the management of TB is urgently needed for designing 
effective tuberculosis prevention and control strategies in the country. 
 
Publication V: In this study, we report for the first time the isolation and identification of 
Nocardia isolates recovered from TB suspects in Northeastern, Tanzania. Twenty 
patients diagnosed as having presumptively Nocardia infections based on microscopic 
and cultural characteristics were confirmed using biomèrieux ID 32C Yeast Identification 
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system and 16S rRNA gene specific primers for Nocardia species and sequencing. 
Biochemically, the majority of the isolates were N. asteroids (n = 8, 40%), N. brasiliensis 
(n = 4, 20%), N. farcinica (n = 3, 15%), N. nova (n = 1, 5%). Other aerobic 
actinomycetales included Streptomyces cyanescens (n = 2, 10%), Streptomyces griseus, 
Actinomadura madurae each (n = 1, 5%). 16S rRNA sequencing identified five members 
of the species (29.4%) N. cyriacigeorgica, four (23.5%) N. farcinica, two (11.7%) N. 
flavorosea and N. testacea each, N. asteroids, N. nova, N. carnea and N. brevicatena one 
(5.9%) each. Our findings suggest that Nocardia species may be an important cause of 
pulmonary nocardiosis that is underdiagnosed or ignored. This underscore needs to 
consider pulmonary nocardiosis as a differential diagnosis when there is a failure of anti-
TB therapy and as a possible cause of human infections.  
 
In general, this dissertation has provided important information gaps that hinder the 
efforts to prevent and control TB disease in Tanzania. The study further shows that MTB 
is the predominant species of the MTC in Tanga and the CAS1_KILI spoligotype the 
predominant strain type. Moreover, the study has demonstrated that majority of TB 
infections in this area are due to the modern TB lineages. The study has also highlighted 
the need to conduct drug susceptibility testing of patients diagnosed at the health facility 
levels since a good proportion of self-presented TB suspects may have already been 
infected with resistant TB strains. The prevalent increase of NTM and pulmonary 
nocardiosis showed in this study has demonstrated that NTMs and Nocardia species may 
be potential causes of human disease in this population, therefore calling for the national 
control programmes to design an integrated preventive and control strategy urgently 
required to combat the disease in the country. Further research in determining the 
prevalence of other pathogens causing TB-like symptoms and the role of NTM and or 
Nocardia co-infections in the progression of TB disease is also required in strengthening 
national’s efforts to prevent and control the disease. 
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Annex 1I: Specimen request and reporting form for TB suspects in Muheza and 
Tanga, Tanzania study 2012/13 
Patient Identification No: _________ 
Patient Name ____________________________ Age (yr):_________Sex: ___ 
Ethnicity: ____________________ Occupation: ________________ 
Village/Ward: ____________________ 
Clinical signs and symptoms (Tick where appropriate) 
1) Chronic cough (> 2 weeks): Yes:_______ No:______  
2)  Blood streaked sputum: Yes:____ No:__________ 
3) Night sweat: Yes:_____  No:______ 
4) Fatigue: Yes:______ No:_______ 
5) Fever: Yes:_______ No:_________ 
6) Dyspnoea (Difficult breathing): Yes:______ No: _______ 
7) Unexpected weight loss: Yes:________ No: _______ 
Concurrent conditions 
1) Tobacco smoking (previous or current): Yes:_____ No: _____ 
2) Diabetes: Yes: ________  No: ______ 
3) *HIV-status: Positive/ Negative / Unknown  (Tick where appropriate) 
NB: 
*Information that can be disclosed optionally. 
Type of TB disease and history 
New TB register No: _____________________  Previous TB register No: __________________ 
MDR case No: ________________________ 
Pulmonary TB:      New case (never treated for ≥ 1 month) 
 Relapse case 
Treatment history: 
First-line drugs: _____________ Second-line (Mention if any) ____________ 
Other treatment: _____________ Failure of treatment  MDR 
 
Origin of request: Research (PhD study) 
Laboratory performing investigation: ______________________________ 
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Type of specimen:  Sputum 
Sputum in preservative (Type of preservative if any): 
_____________________ 
Date specimen was collected: _____/______/___________ Specimen ID number: 
____________ 
Local laboratory microscopy results: 
    Negative  
    Doubtful  
1+  
2+  
3+  
Microscopy technique used (Tick where appropriate) 
Hot Ziehl- Nelsen    Direct smear 
Kinyoun (Cold staining)   Concentrated smear 
Fluorescence 
Person requesting examination:  
Name: ___________________________________ 
Signature: ________________________________ 
Position: _________________________________ 
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Influenza Research Surveillance 
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